LivaNova PLC (LIVN)
| Market Cap | 2.58B |
| Revenue (ttm) | 1.24B |
| Net Income (ttm) | 23.68M |
| Shares Out | 54.30M |
| EPS (ttm) | 0.43 |
| PE Ratio | 111.11 |
| Forward PE | 13.63 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,136,127 |
| Open | 47.03 |
| Previous Close | 47.49 |
| Day's Range | 47.03 - 49.31 |
| 52-Week Range | 43.15 - 64.48 |
| Beta | 0.99 |
| Analysts | Buy |
| Price Target | 67.14 (+41.08%) |
| Earnings Date | Feb 19, 2025 |
About LIVN
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable p... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for LIVN stock is "Buy." The 12-month stock price forecast is $67.14, which is an increase of 41.08% from the latest price.
News
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced that Brain Stimulation published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study.
LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, taking place Dec. 6-10 in Los Angeles.
LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC announced Vladimir Makatsaria, CEO, will present a general business update during fireside chats at Stifel, Wolfe and Piper in New Y...
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.
LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript
LivaNova PLC (NASDAQ:LIVN) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President-Corporate Development & IT Vladimir Makatsaria - Chi...
LivaNova Reports Third-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance.
LivaNova: Economics Should Start Making Sustained Improvements
LivaNova's Essenz product drives revenue growth, with successful rollout and premium pricing boosting guidance despite tough comparisons into the end of the year. Neuromodulation revenues, particularl...
LivaNova Appoints Susan Podlogar as a New Director
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced its Board of Directors has appointed Susan Podlogar to the Board, effective October 8, 2024.
LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts
Shares of LivaNova Plc LIVN Tuesday climbed along with several other big stocks.
LivaNova to Announce Third-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC will host a conference call to discuss its third-quarter 2024 results on Wednesday, October 30, 2024.
LivaNova to Present at the Baird Global Healthcare Conference
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today announced Vladimir Makatsaria, CEO, will present in a fireside chat at the Baird 2024 Conference in NYC at 10:15 am ET on Sept...
LivaNova PLC (LIVN) Q2 2024 Earnings Call Transcript
LivaNova PLC (NASDAQ:LIVN) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Matthew Dodds – Senior Vice President-Corporate Development and IT Vladimir Makatsaria – Chie...
LivaNova Reports Second-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC reported results for the quarter ended June 30, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.
Federman & Sherwood Investigates LivaNova USA, Inc. for Data Breach
OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates LivaNova USA, Inc. for Data Breach.
LivaNova to Announce Second-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results ...
LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova announced preliminary results for the unipolar cohort of the RECOVER study, assessing use of VNS Therapy in treatment-resistant depression.
LivaNova to Present at the Goldman Sachs Healthcare Conference
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova announced Vladimir Makatsaria, CEO, will present a fireside chat at the Goldman Sachs Conference in Miami, Florida at 1:20 pm ET on June...
LivaNova PLC (LIVN) Q1 2024 Earnings Call Transcript
LivaNova PLC (NASDAQ:LIVN) Q1 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President, Corporate Development & IT Vladimir Makatsaria - Chief E...
LivaNova Reports First-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.
LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced that Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer, effective May 13, 2024.
LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova's wholly-owned U.S. subsidiary, LivaNova USA, Inc., is providing notice to U.S. patients regarding a cybersecurity incident in late 2023.
LivaNova to Announce First-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova will host a conference call to discuss its first-quarter 2024 results on Wed, May 1, 2024 at 1 p.m. London time (8 a.m. ET).
LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced its OSPREY clinical study has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated.
LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 issued in a private offering.
LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 in a private offering.